Recently, shares of Henry Schein Inc (Symbol: HSIC) have climbed above the average analyst 12-month target price of $74.67, trading at $74.84 per share. Typically, when a stock reaches its target, analysts usually face two options: downgrade their valuation or increase their target price. The decision often hinges on the company’s business developments that could be driving the stock’s upward momentum. If the outlook is positive, it might be time for a target price adjustment.
The average price target for Henry Schein Inc comes from 12 analysts within the Zacks coverage universe. However, this average represents a range of opinions. For instance, one analyst is predicting a price of just $55.00, while another sees potential as high as $83.00. The standard deviation among these targets is $7.631, indicating a notable variation in outlooks amongst analysts.
Understanding the average HSIC price target helps investors consider a collective perspective rather than relying on a single analyst’s opinion. Now that HSIC has surpassed the average target price of $74.67, investors have a valuable opportunity to evaluate whether this is merely a stopping point toward a higher target or if the valuation has become too stretched, prompting them to reconsider their investments. The table below outlines the current sentiment among analysts covering Henry Schein Inc:
| Recent HSIC Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Months Ago | 3 Months Ago |
| Strong buy ratings: | 5 | 5 | 5 | 5 |
| Buy ratings: | 0 | 0 | 0 | 0 |
| Hold ratings: | 6 | 6 | 6 | 6 |
| Sell ratings: | 1 | 1 | 1 | 1 |
| Strong sell ratings: | 1 | 1 | 1 | 1 |
| Average rating: | 2.41 | 2.41 | 2.41 | 2.41 |
The average rating in the table ranges from 1 (Strong Buy) to 5 (Strong Sell). Data used in this article is provided by Zacks Investment Research via Quandl.com. For the latest Zacks research report on HSIC — available for free.
The Top 25 Broker Analyst Picks of the S&P 500 »
Also see:
• Institutional Holders of DXM
• Funds Holding NKGN
• HROW Insider Buying
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
